Amanda Denney, MD
Endocrinology, Diabetes & Metabolism · Cincinnati, OHNPI 1003871047
Payments from drug & device makers
Across 539 payments — averaging $339.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$102K
- Lilly USA, LLC$44K
- Boehringer Ingelheim$33K
- Dexcom, Inc.$831
- AstraZeneca$631
- Sanofi-aventis U.S. LLC$512
- plus $2K from 27 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 167 | $101,796 |
| Lilly USA, LLC | 112 | $44,484 |
| Boehringer Ingelheim | 90 | $32,520 |
| Dexcom, Inc. | 35 | $831 |
| AstraZeneca(2 entities) | 21 | $631 |
| Sanofi-aventis U.S. LLC | 20 | $512 |
| Insulet Corporation | 12 | $395 |
| Amgen | 6 | $176 |
| Novartis | 10 | $173 |
| Xeris Pharmaceuticals, Inc. | 3 | $152 |
| Boston Scientific | 1 | $145 |
| BETA Bionics, Inc. | 1 | $139 |
| Corcept Therapeutics | 7 | $138 |
| Sequel Med Tech, LLC | 1 | $138 |
| Abbott | 5 | $104 |
| Medtronic | 2 | $102 |
| AbbVie | 6 | $93 |
| Shire North American Group Inc | 5 | $85 |
| Tandem Diabetes Care, Inc. | 3 | $82 |
| Johnson & Johnson | 6 | $77 |
| Pfizer | 3 | $58 |
| Mannkind Corporation | 3 | $45 |
| Merck | 3 | $42 |
| Amryt Pharma Holdings Ltd | 2 | $41 |
| Valeritas, Inc. | 2 | $38 |
| Vivus LLC | 3 | $35 |
| Lifescan, Inc. | 2 | $33 |
| Amarin Pharma, Inc. | 2 | $26 |
| Currax Pharmaceuticals LLC | 2 | $26 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $21 |
| Radius Health, Inc. | 1 | $18 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| Senseonics, Incorporated | 1 | $13 |
How this compares
$183,185 in reported general payments places this provider in the 90th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
See all endocrinology, diabetes & metabolism providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Cincinnati
- Nelson WattsCincinnati$348K
- Shawn PeavieCincinnati$201K
- Robert CohenCincinnati$136K
- Shailendra PatelCincinnati$68K
- Toby BriskinBedford$9.8M
- Charles SmithCanton$5.3M
- Kevin PantaloneCleveland$4M
- Elena ChristofidesColumbus$3.5M
- Arvind KrishnaCanton$3.1M
- Bartolome BurgueraCleveland$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.